【布汝斯-艾尔沃德 WHO 谈武汉新冠病毒】

 

 

"There is only one drug right now that we think may have real efficacy and that's Remdesivir," 

Bruce Aylward, an assistant director-general of the World Health Organization (WHO), said at a press conference in Beijing.
布汝斯-艾尔沃德 医学博士

加拿大流行病学家 同时供职世卫组织
WHO officials said clinical trials for Remdesivir in humans are now taking place and results should be available within weeks.

 

艾尔沃德 医生的这句话，很重要，

如何精确地翻译和领悟需要点儿思考。

 

原文，直译是：

目前只有一个药，我们认为，也许有真效，

即 瑞木岱西维尔。

 

1，鼓噪 双黄连液 抗新冠病毒 纯属欺诈和商业犯罪，必须追查！

 

2，曹彬教授的武汉瑞药试验堪虞堪忧，还有一个多月，能否如期如愿完成，存疑。另，试验已经三周，有何端倪眉目，应有所显露了！

 

3，应知医学药学试验的设计和基本要素，条件的严苛性，不能缺少基本的条件和时间过程。

 

4，布汝斯说瑞药是可能唯一真有效药物，是实话实说，关键是限定词 may 也许。换言之，也许没效。他的话其实是对目前吹嘘的其它药物和乱七八糟的试验的否定，棒杀的对！我支持。（氯喹等就是瞎哄哄的例子之一，当然也许真有效果的还在路上，路漫漫其修远兮，吾将上下而求索 。科研医学临床要看实效，不是也不能一蹴而就，得来全不费工夫！）

 

5，瑞药对Ebola伊波拉病毒基本无效，而非本文吹的很有效！这是我对此文持批判的根本！

 

6，国内现在是病急乱投医乱用药，部分心情可以理解。所以200多试验项目中有20个可以理解和允许，毕竟八仙过海，不能一棵歪脖树上吊死。

 

7，李兰娟教授说有两三种药，体外试验有抗新冠病毒作用，看后哑然失笑！1，体外效果和人体内差108000里，2，科学试验没这么无云就放炮打雷的。等有临床效果再宣称什么，来得及， 慌什么？3，我有更好的药物，100%见效，硫酸！强酸，火碱，能用吗？！笑话！

 

Dr. Bruce Aylward, 

former Assistant Director-General of the WHO and 

senior advisor to WHO Director-General.

 

 

Dr Bruce Aylward received his MD at Memorial University, St. John’s, Newfoundland, in Canada in 1985.

So first, what has China done?

 

艾尔沃德，明人快语，直切主题的演讲

 

In the face of a previously unknown disease, China has taken one of the most ancient approaches for infectious disease control and rolled out probably the most ambitious, and I would say, agile and aggressive disease containment effort in history. China took old-fashioned measures, like the national approach to hand-washing, the mask-wearing, the social distancing, the universal temperature monitoring. 

 

艾尔沃德 对中国的战疫举措感悟至深，

他称之为 

中国采用了最古老的，

最大手笔的战疫措施，

超乎了人们的想象力。

 

But then very quickly, as it started to evolve, the response started to change. And it moved from this sort of one-size-fits-all approach to a science-and-risk-based approach, which was really tailored to allow it to use different containment approaches and measures,depending on the context, the capacity and really the nature of the coronavirus circulation. 

 

So they refined the strategy as they moved forward, and this is an important aspect as we look to how we might use this going forward.A couple of things have differentiated. The first, they took this old approach and then turbo-charged it with modern science and modern technology in a way that was unimaginable even a few years ago. Just a couple of small examples. 

 

As they cleared these giant hospitals to make space for overwhelming numbers of COVID-19 cases, they moved a huge amount of the routine provision of medical services onto online platforms and other mechanisms that they’ve really come to a cutting edge with. And when we were in Sichuan, wondering how they were working with the remote areas, they showed us that they have prioritized a roll out of a 5G platform so that they could do real-time contact, support, with investigators in the field, we asked to see it, and in two minutes up on the big screen they pull up an epidemiological investigation team that was in the field, was having problems with something hundreds of kilometers away, and was getting walked through it by the top experts from the province. 

 

So it brought a lot of attention to understand this strategy, because it’s fundamentally different to the way most people think about approaching a dangerous respiratory pathogen in the modern era.And this brought us to the second issue about how did they make it happen, make the strategy actually translated in impact? 

 

What they’ve done has only been possible because of tremendous collective commitment and will of the Chinese people from the most bottom-level community leaders we met and talked to, to the governors at the top. It was an extraordinary, what we call all-of-government, all-of-society approach that many of you are feeling because you live here and you operate it. But it is rare to see that.

There was one aspect of this that struck us as particularly important. You’ve been hearing about the challenges we are having with the global supply chain and PPE, and many countries start piling and hoarding this. But what we found out was, even though every province was suffering outbreaks, was getting infected, the governors were prioritizing the movement of medical teams and PPE out to Hubei and Wuhan. That’s a very important method for the rest of the world about how we work in the kind of solidarity and collaborative action that’s going to be needed to beat this virus.So first, understanding the strategy was key, then how it was applied and got to the incredible level of application. 

 

But the key thing is, of course, has it made a difference? 

Has China made an impact on this virus? That’s the next question.And it’s the opinion of the joint mission, after looking at it very closely and in different ways, that there is no question that China’s bold approach to the rapid spread of  this new respiratory pathogen has changed the course of what was a rapidly-escalating and continues to be deadly epidemic.I think one of the most compelling statistics is, when I arrived here on the first day, just over two weeks ago, I don’t remember the day now, I think it’s 9thor 10thof February, anyway, there were 2,478 new cases of COVID-19 being reported every single day, 2,500 new cases being reported every single day when I arrived. 

 

布汝斯-艾尔沃德 

在北京 WHO-China 有关武汉新冠病毒发布会上

讲话全文：（WHO提供）

 

 【 艾尔沃德谈新冠病毒全文】?

 

 

世卫组织萨斯-2 考察团来到中国北京，

先去了四川，广东，然后到武汉，

又回到北京。

 

前几天 有几只菜鸟叽叽喳喳，

说我国掩盖灾情，不让考察团去湖北武汉，

事实打了这帮小丑一记漂亮的耳光！

 

另外几只 喳喳唧唧，

说美国病毒专家来中国是为了窃取标本，

其实，这次世卫组织考察团12名成员中

当然有美国专家参与。

 

害怕论，遮掩论，阴谋论，盗窃犯 的

这些谣言又被击的粉碎！

 

奉劝那些猪鼻子插葱充象的货，

以后少装大尾巴狼！

 

Merdad Parsey, MD, PhD 

Gilead’s Chief Medical Officer, 

美国吉利德药厂 首席医务官 帕希

 

He completed his MD and PhD at the 

University of Maryland, Baltimore, 

               his residency in Internal Medicine at 

Stanford University and his fellowship in Pulmonary and                        Critical Care Medicine at the 

University of Colorado.

 

He was Assistant Professor of 

Medicine and Director of Critical Care Medicine at the 

New York University School of Medicine.